Table 1 Impact of targeted cellular senescence-related therapies on cardiovascular disease.
From: The role of cellular senescence in cardiovascular disease
Cardiovascular disease | Drug targets or mechanisms | Effect | Refs |
|---|---|---|---|
Hypertension | The shortening of arterial telomeres | Promote | [49] |
Hypertension | Activation of the P53/P21 signaling pathway | Promote | [49] |
Hypertension | Rapamycin inhibiting the mTOR signaling pathway | Partially alleviates | [55] |
Atherosclerosis | Inhibition of glutaminase | Alleviate | [93] |
Atherosclerosis | Genetic ablation of gpnmb-positive cells | Alleviate | [95] |
Atherosclerosis | D & Q can reduce the expression level of aging markers | Alleviate | [95] |
Atherosclerosis | ABT-263 selectively eliminate senescent cells | Alleviate | [96] |
Myocardial infarction | Venetoclax attenuating SASP-associated inflammatory responses | Alleviate | [99] |
Myocardial infarction | SIRT1 boost the anti-apoptotic and angiogenic capacities of senescent mesenchymal stem cells | Alleviate | [111] |
Heart failure | SIRT6 preventing the differentiation of fibroblasts towards myofibroblast differentiation | Alleviate | [80] |
Heart failure | SIRT1 enhances PGC-1αactivity | Alleviate | [126] |
Heart failure | ABT-263 improve left ventricular contractile function, reduce myocardial fibrosis and hypertrophy | Alleviate | [95] |
Arrhythmias | Quercetin inhibiting TGF-β/Smads pathway | Alleviate | [150] |
